sarcomas

mechanical gears shifting
Biotech

Adaptimmune's cell therapy hits key goal in pivotal sarcoma test

Adaptimmune is prepping for another FDA submission after its cell therapy was tied to a 42% response rate in a phase 2 sarcoma trial.
Gabrielle Masson Nov 13, 2024 2:57pm
finch canary cage free bird release

FDA frees Salarius’ rare cancer asset from clinical hold

May 9, 2023 11:20am
Liposarcoma sarcoma

Salarius pauses enrollment of sarcoma trial after patient death

Oct 18, 2022 9:50am
cancer newspaper

Adaptimmune's T-cell therapy clears efficacy bar in solid tumors

Nov 12, 2021 7:05am
Laboratory

ASCO: Adaptimmune’s cell therapy shrinks 39% of rare sarcomas

May 19, 2021 5:00pm
Rain Therapeutics

Rain tees up $100M IPO to push ex-Daiichi cancer drug into phase

Apr 5, 2021 9:45am